Allogene Therapeutics, Inc. ALLO
Set alert
1.13 USD +0.04 +3.67%
As of Nov 3, 11:30 AM ET
1.10 Day range 1.14
1.04 52-week range 4.46
- YTD
- -17.52%
- 1 year
- -4.24%
- Open
- 1.12
- Prev close
- 1.09
- Mkt cap
- 390.40M
- Vol
- 5.47M
- Avg vol
- 5.99M
- EPS
- -0.66
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.10
- High
- 1.14
- Forward P/E
- -1.50
- Beta
- 0.84
- Short ratio
- 11.46
- Inst. own
- 80.20%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 7, 2024
- 50-d avg
- 2.47
- 200-d avg
- 2.83
- 1y target
- 9.04
Analyst view
Consensus: buy
Buy
Price target (mean) 9.04 +700.1% upside
Now 1.13
- Target (low)
- 3.00
- Target (mean)
- 9.04
- Target (high)
- 14.00
Ratings (0m) 18 13 buy · 5 hold · 0 sell
- Strong buy4
- Buy9
- Hold5
- Sell0
- Strong sell0
Recommendation trend
- This month 18
- 1 month ago 18
- 2 months ago 17
- 3 months ago 17
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.32709 | -0.41 – -0.28 | -0.51 | +35.9% | 12.11K | -42.3% | 11 |
| Next quarter | -0.3475 | -0.43 – -0.29 | -0.38 | +8.6% | 4.17K | -81.0% | 9 |
| Current year | -1.31 | -1.38 – -1.17 | -2.09 | +37.1% | 31.37K | -67.0% | 10 |
| Next year | -1.38 | -1.71 – -1.23 | -1.31 | -5.1% | 47.18K | +50.4% | 15 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2024 | Piper Sandler | Maintained | Overweight | Overweight |
| Nov 8, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Oct 30, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 15, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 9, 2024 | Citigroup | Maintained | Buy | Buy |
| Aug 9, 2024 | Truist Securities | Reiterated | Buy | Buy |
| Aug 8, 2024 | Canaccord Genuity | Maintained | Buy | Buy |
| May 31, 2024 | Piper Sandler | Initiated | — | Overweight |
| May 21, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| May 16, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 15, 2024 | Truist Securities | Maintained | Buy | Buy |
| May 14, 2024 | Stifel | Maintained | Hold | Hold |
| Mar 19, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 15, 2024 | RBC Capital | Reiterated | Outperform | Outperform |
| Feb 27, 2024 | JP Morgan | Maintained | Overweight | Overweight |
| Jan 19, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jan 5, 2024 | Guggenheim | Downgrade | Buy | Neutral |
| Jan 5, 2024 | JMP Securities | Downgrade | Market Outperform | Market Perform |
| Dec 8, 2023 | Citigroup | Initiated | — | Buy |
| Nov 15, 2023 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Sep 25, 2023 | JP Morgan | Maintained | Overweight | Overweight |
| Aug 7, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 3, 2023 | Oppenheimer | Reiterated | Outperform | Outperform |
| Aug 3, 2023 | EF Hutton | Reiterated | Buy | Buy |
| Jul 12, 2023 | Truist Securities | Maintained | Buy | Buy |
| Jun 20, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 16, 2023 | Canaccord Genuity | Reiterated | Buy | Buy |
| Jun 5, 2023 | JMP Securities | Reiterated | — | Market Outperform |
| Jun 5, 2023 | EF Hutton | Reiterated | Buy | Buy |
| May 26, 2023 | EF Hutton | Reiterated | Buy | Buy |